Ai In Biopharma

Antibody developability checks are moving into discovery instead of waiting for development

FairJourney Bio's Maria Gonzalez-Pajuelo says developability has become a much more important consideration during antibody discovery.

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte estimated top biopharma firms could capture $5-7B in AI value. McKinsey and ISPE material show why timelines and validation still lag.

Biopharma's $300 Billion Patent Cliff Is Driving Its Strongest M&A Cycle Since the Pre-Pandemic Peak

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

AI-Driven Amino Acid Drugs Surface as a Promising Treatment for Eye Conditions

The rapid evolution of artificial intelligence (AI) promises to revolutionize multiple sectors, and one area seeing tangible benefits is drug development. Historically, the creation of new medicines was a time-consuming endeavor, but AI-driven amino acid research is proving to accelerate the early developmental stages and get drugs to the market faster. Researchers at the Wilmer…